Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
01:48pm, Tuesday, 09'th Jul 2024
uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
10:35am, Tuesday, 09'th Jul 2024
uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
Why Is uniQure (QURE) Stock Up 51% Today?
10:27am, Tuesday, 09'th Jul 2024
UniQure (NASDAQ: QURE ) stock is on the rise Tuesday after the company provided investors with interim clinical data from a PhaseI/II clinical trials for AMT-130. These clinical trials are evaluating
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the compo
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
07:05am, Monday, 01'st Jul 2024
Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 202
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
07:05am, Monday, 01'st Jul 2024
~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's dise
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
07:05am, Tuesday, 07'th May 2024
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
09:20am, Wednesday, 28'th Feb 2024
UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
07:05am, Wednesday, 28'th Feb 2024
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interacti
uniQure: The Valuation Got More Attractive
02:25pm, Thursday, 01'st Feb 2024
uniQure is valued here as a pre-revenue company assessing its liquidation value, value of potential cash flows from HEMGENIX sales and estimating the worth of its future R&D efforts. In 2023, uniQure
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease
07:05am, Tuesday, 19'th Dec 2023
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history
HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years post-tr
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:05am, Friday, 08'th Dec 2023
LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
07:05am, Wednesday, 29'th Nov 2023
LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V.
